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Purpose: We hypothesize that sex steroids induce sex-specific and/or opposite effects in the lacrimal and meibomian
glands and that these actions may influence the prevalence of dry eye syndrome. The objective of this study was to begin
to test this hypothesis.
Methods:  Lacrimal  and  meibomian  glands  were  obtained  from  ovariectomized  mice  that  had  been  treated  with
testosterone or control vehicle for 14 days. Samples were processed for the isolation of RNA, and analyzed for differentially
expressed mRNAs using CodeLink Bioarrays and quantitative real-time PCR (qPCR) techniques. Data were compared
to those obtained following testosterone treatment of orchiectomized mice, as well as after the administration of 17β-
estradiol and/or progesterone to ovariectomized mice.
Results: Our findings demonstrate that testosterone regulates the expression of thousands of genes in the lacrimal and
meibomian glands of ovariectomized mice. The magnitude and extent of these hormonal effects, which encompassed
numerous biological, molecular, and cellular ontologies, was tissue-dependent. Particularly notable was the androgen
stimulation of meibomian gland genes related to lipid metabolic pathways, and the suppression of genes associated with
keratinization. Many of the genes regulated by testosterone in female tissues were identical to those controlled by
androgens in male lacrimal and meibomian glands. However, some genes were modulated in a sex-specific manner. In
addition, a number of the androgen-regulated genes in female glands were altered in the opposite direction by 17β-estradiol
and/or progesterone.
Conclusions: Our results support our hypothesis that sex steroids may induce sex-specific and/or opposite effects in the
lacrimal and meibomian glands. Whether these actions contribute to the prevalence of dry eye remains to be determined.
Sex steroid hormones, such as androgens and estrogens,
exert significant effects on almost every cell, tissue, and organ
system of the body [1]. However, these hormone actions may
not be the same in both males and females. Rather, sex steroid
influence may be sex-specific. For example, sex steroids elicit
sex-specific effects on many tissues (e.g. hippocampus, spinal
cord,  vasculature,  muscle,  and  liver)  and  cells  (e.g.
preadipocytes,  neutrophils,  and  antigen-presenting  cells)
[2-9]. Sex steroids may also induce opposite [10-14], and even
antagonistic  [15],  influences,  such  as  on  sebaceous  gland
activity,  cerebrovascular  function,  microtubule
polymerization,  chronic  allograft  nephropathy,
autoimmunity,  and  the  cystic  fibrosis  transmembrane
conductance  regulator  (i.e.  a  chloride  channel).  These
differential actions of sex steroids in males and females may
contribute  to  a  variety  of  conditions,  including  stress,
atherosclerosis,  coronary  heart  disease,  fat  distribution,
inflammation,  autoimmune  disease,  infection,  pain
syndromes, stroke, and lung development [2-5,8-10,14].
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We hypothesize that sex-specific and/or opposite effects
of sex steroids also occur in the lacrimal and meibomian
glands and may influence the prevalence of dry eye disease.
In support of this hypothesis, investigators have reported that
sex steroid actions on the transcription of certain genes, the
translation  of  the  corresponding  proteins,  and  the
development  of  paradoxical  inflammation  in  the  lacrimal
gland are sex-biased [15-21]. Moreover, we have discovered
that sex and sex steroid hormones are critical factors in the
pathogenesis  of  dry  eye  syndromes  [22-31],  which  occur
predominantly in women [32]. We have also discovered that
androgens  may  suppress,  and  estrogens  may  promote,
aqueous-deficient and/or evaporative dry eye [22-26,31]. We
hypothesize  that  these  opposing  sex  steroid  actions  may
involve antagonist effects between androgens and estrogens
in the lacrimal and meibomian glands.
However,  whether  sex  steroids  exert  sex-specific  or
antagonistic effects in ocular adnexal tissues is unknown. The
purpose of this study was to determine whether sex steroids
do  elicit  sex-specific  and/or  opposite  effects  in  both  the
lacrimal  and  meibomian  glands.  Towards  this  end,  we
examined  the  impact  of  testosterone  on  glandular  gene
expression  in  ovariectomized  mice,  and  compared  these
effects to those found in androgen-treated orchiectomized
mice.  We  also  compared  the  testosterone-induced  gene
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1553alterations in the female lacrimal and meibomian glands to
those  elicited  by  17β-estradiol,  progesterone,  or  both
hormones together in these tissues.
METHODS
Animals and hormone treatment: Age-matched and young
adult BALB/c mice, that were ovariectomized at 8 weeks of
age, were obtained from Taconic Laboratories (Germantown,
NY). Animals were housed in constant temperature rooms
with fixed light/dark intervals of 12 h duration. Ten days after
surgery,  pellets  containing  vehicle  (cholesterol,
methylcellulose,  lactose)  or  testosterone  (10  mg)  were
implanted subcutaneously in the ovariectomized mice. The
pellets were purchased from Innovative Research of America
(Sarasota, FL) and were designed for the constant release of
placebo or physiological amounts of androgen (for a male
[33-36]) for 3 weeks. After 14 days of treatment, mice (n=5-6
mice/  condition/  experiment)  were  sacrificed  by  CO2
inhalation and exorbital lacrimal and meibomian glands were
removed. The meibomian glands were excised from the upper
and  lower  lids  under  direct  visualization  with  a
biomicroscope. This surgical procedure involved making a
small incision near the inner corner of the eyelid, separating
skin and subcutaneous tissue from the inner to outer aspect of
the lid, and then removing skin from the meibomian glands
by cutting at the mucocutaneous junction. Following these
steps,  the  palpebral  conjunctiva  was  removed  from  the
meibomian glands, and the glands were dissected from the
remaining  tissue  by  starting  at  the  outer  lid  corner  and
carefully  avoiding  an  adjacent  vein.  Tissues  were  pooled
according to group (n=10-12 glands/ sample) and processed
for RNA analysis. All studies with mice were approved by the
Institutional  Animal  Care  and  Use  Committee  of  The
Schepens Eye Research Institute (Boston, MA) and adhered
to the Association for Research in Vision and Ophthalmology
Statement for the Use of Animals in Ophthalmic and Vision
Research.
Molecular biological procedures: To determine the influence
of  testosterone  on  lacrimal  and  meibomian  gland  gene
expression, total RNA was extracted from tissues by using
TRIzol reagent (Invitrogen Corp., Carlsbad, CA). Lacrimal
tissue  RNA  was  further  purified  with  RNAqueous  spin
columns (Ambion, Austin, Tx). Glandular RNA samples were
exposed  to  RNase-free  DNase  (Invitrogen),  examined
spectrophotometrically at 260 nm to determine concentration
and analyzed with a RNA 6000 Nano LabChip and an Agilent
2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA) to
verify RNA integrity.
Gene expression was assessed by using CodeLink Uniset
Mouse I Bioarrays (~10,000 genes; Amersham Biosciences/
GE Healthcare, Piscataway, NJ). The RNA samples were
processed for CodeLink Bioarray hybridization, according to
published procedures [37]. In brief, cDNA was synthesized
from RNA (2 µg) with a CodeLink Expression Assay Reagent
Kit  (Amersham,  Piscataway,  NJ)  and  purified  with  a
QIAquick purification kit (Qiagen, Valencia, CA). Samples
were then dried, and cRNA was produced with a CodeLink
Expression Assay Reagent Kit (Amersham), recovered with
an  RNeasy  kit  (Qiagen)  and  quantified  with  an  UV
spectrophotometer.  Fragmented,  biotin-labeled  cRNA  was
incubated  and  shaken  (300  rpm  shaker)  on  a  CodeLink
Bioarray at 37 °C for 18 h. After this time period, the Bioarray
was washed, exposed to streptavidin-Alexa 647, and scanned
by utilizing ScanArray Express software and a ScanArray
Express HT scanner (Packard BioScience, Meriden, CT) with
the  laser  set  at  635  nm,  laser  power  at  100%,  and
photomultiplier tube voltage at 60%. Scanned image files
were appraised by utilizing CodeLink image and data analysis
software  (Amersham),  which  yielded  both  raw  and
normalized hybridization signal intensities for each array spot.
The spot intensities (~10,000 ) on the microarray image were
standardized to a median of 1. Normalized data, with signal
intensities exceeding 0.50 for the meibomian gland and 0.75
for the lacrimal gland, were evaluated with GeneSifter.net
software  (Geospiza,  Seattle,  WA).  This  comprehensive
program also generated gene ontology and z-score reports.
These  ontologies  encompassed  biological  processes,
molecular  functions  and  cellular  components  and  were
organized according to the guidelines of the Gene Ontology
Consortium [38]. Gene expression data were analyzed without
and with log transformation and statistical evaluation of these
data  was  performed  with  Student’s  t-test  (two-tailed,
unpaired)  with  GeneSifter.net  software.  Genes  that  were
expressed  in  similar  or  opposite  directions  in  different
experiments  were  identified  by  using  the  GeneSifter.net
intersector program (Geospiza). The data from the individual
Bioarrays  (n=6)  are  accessible  for  download  through  the
National  Center  for  Biotechnology  Information’s  Gene
Expression  Omnibus  (GEO)  via  series  accession  number
GSE3995.
Real time PCR procedures: The differential expression of
selected genes was confirmed by using quantitative real-time
PCR (qPCR), as previously described [33,39]. In brief, sense
and  anti-sense  primers  were  designed  by  utilizing  Primer
Express Software, version 1.5a (Applied Biosystems, Inc.,
Foster City, CA). The qPCR reactions were performed with
Applied  Biosystems’  SYBR  Green  PCR  Master  Mix,
MicroAmp  Optical  96-Well  Reaction  Plates,  ABI  PRISM
Optical  Adhesive  Covers  and  the  GeneAmp  7900  HT
Sequence Detection System. Gene expression was calculated
by using either the Relative Standard Curve Method or the
Comparative CT Method, and standardizing levels to that of
glyceraldehyde-3-phosphate  dehydrogenase  or  tubulin  δ1
mRNA. Dissociation curves were examined to ensure the
absence of secondary PCR products.
RESULTS
Androgen influence on gene expression in female lacrimal
and  meibomian  glands:  To  determine  the  influence  of
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1554testosterone  on  lacrimal  and  meibomian  gland  gene
expression,  tissues  were  obtained  from  placebo-  and
androgen-treated,  ovariectomized  mice  (n=5-6/group/
experiment) and processed for analysis by utilizing CodeLink
Uniset  Mouse  I  Bioarrays.  Examination  of  non-  and  log-
transformed data from 3 separate experiments demonstrated
that  testosterone  significantly  altered  the  expression  of
thousands of genes in female ocular tissues. Androgen action
significantly upregulated 768 genes (e.g. transforming growth
factor  β1  and  β3),  and  significantly  downregulated  1,350
genes (e.g. pancreatic lipase related protein 1; Table 1 and
Table  2),  in  the  lacrimal  gland.  Moreover,  testosterone
administration increased the expression of 726 genes (e.g.
glutathione peroxidase 3) and decreased the activity of 283
genes (e.g. small proline-rich protein 2A) in the meibomian
gland (Table 1 and Table 3). The magnitude of these hormonal
effects was tissue-dependent. Testosterone treatment induced
a ≥10 fold change in the expression of over 45 lacrimal gland
genes, and elicited a ≥2 fold response in the activity of 23
meibomian gland genes.
The  influence  of  androgen  exposure  was  particularly
notable in its significant stimulation of such ontologies as cell
cycle, transferase activity and chromosomes in the lacrimal
gland (Table 4), and protein transport, oxidoreductase activity
and  mitochondria  in  the  meibomian  gland  (Table  5).
Testosterone treatment was also associated with a significant
suppression  of  pathways  linked  to  translation,  structural
molecule activity and ribosomes in lacrimal tissue, and the
immune response, receptor binding and plasma membranes in
the meibomian gland. Of particular interest was the significant
androgen impact on the expression of genes linked to multiple
lipid  metabolic  processes  (e.g.  biosynthesis,  transport,
oxidation) in meibomian tissue (Table 6). Also striking was
the testosterone suppression of genes related to keratinization
(z score=10.2) and cell fate commitment (z score=3.2) in the
meibomian gland (Table 7).
To verify in part the CodeLink Bioarray results, selected
genes were analyzed by qPCR. This experimental approach
confirmed the effect of testosterone on all tested genes (Table
8).
Surprisingly, the effects of testosterone on the lacrimal
and meibomian gland were not entirely tissue-specific. As
shown  in  Table  9,  androgen  treatment  caused  analogous
changes in the expression of 127 genes in both tissues, and
opposite responses in 165 genes. Genes regulated in the same
manner  included  vascular  endothelial  growth  factor  A,
hyaluronan mediated motility receptor, and lipocalin 3 (Table
10). Those controlled in a different way included chemokine
binding  protein  2,  cholecystokinin,  and  matrix
metalloproteinase 3 (Table 10).
Comparative effects of androgens on gene expression in male
and  female  lacrimal  and  meibomian  glands:  We  have
previously  discovered  that  testosterone  treatment
significantly  influences  the  expression  of  over  2,000  and
1,500  genes  in  the  lacrimal  and  meibomian  glands,
respectively,  of  orchiectomized  mice  [40].  To  examine
whether these androgen actions are analogous to those found
in ovariectomized mice, we compared the data from the earlier
studies  (n=10-14  glands/  sample/  experiment;  n=3
experiments/ study) with orchiectomized mice to those in the
present  investigation.  All  gene  expression  results  were
generated  with  CodeLink  Uniset  Mouse  I  Bioarrays  and
analyzed with GeneSifter software.
Our analysis of log transformed data demonstrated that
testosterone  administration  significantly  altered  the
expression of many of the same genes in both ovariectomized
and orchiectomized mice. This hormonal control included
1,072 similar genes in lacrimal glands and 285 similar genes
in meibomian glands. The nature (i.e. up- or down-regulation)
of the androgen effects was identical in 95.5% of the lacrimal
gland genes, and 77.6% of the meibomian gland genes.
TABLE 1. INFLUENCE OF TESTOSTERONE ON GENE EXPRESSION IN THE FEMALE LACRIMAL AND MEIBOMIAN GLANDS.
  Genes ↑ Genes ↓ Total
Lacrimal gland
No transformation 704 1,286 1,990
Log transformation 725 1,304 2,029
Total 768 1,350 2,118
Meibomian gland
No transformation 697 259 956
Log transformation 693 273 966
Total 726 283 1,009
Data were evaluated with and without log transformation. The numbers of common and non-overlapping genes between
analytical categories  were  determined,  and  then  the  total  numbers  were  calculated.  The  expression  of  listed  genes  was
significantly (p <0.05) up (↑)- or down (↓)-regulated by testosterone treatment.
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1557To further compare testosterone influence on glandular
gene expression in female and male mice, we focused on genes
in  female  tissues  with  relatively  high  array  intensities,
expression ratios (i.e. compared to the placebo-treated group),
and significant differences (i.e. versus placebo). These more
stringent  criteria  (lacrimal=p  <0.001;  intensity  >2.0;  ratio
>1.8;  meibomian=p  <0.01;  intensity  >1.0;  ratio  >1.35)
identified 173 (8.7% of the total) and 80 (8.4% of the total)











cell cycle 54 48 4.42 -1.43
mitotic cell cycle 25 18 4.02 -0.94
DNA metabolic process 35 25 3.78 -2.01
protein metabolic process 98 248 -2.06 2.45
anatomical structure development 81 173 -2.51 -1.66
multicellular organismal process 119 231 -2.52 -2.88
translation 5 62 -2.64 7.28
cellular protein metabolic process 96 242 -2.02 2.36
proteolysis 30 89 -1.59 2.06
protein amino acid phosphorylation 30 36 -0.44 -3.47
signal transduction 113 152 0.67 -4.06
cell communication 122 169 0.14 -4.59
Molecular function
transferase activity, transferring acyl groups 15 5 3.18 -2.35
small GTPase regulator activity 13 8 2.47 -1.38
vitamin binding 10 12 2.07 0.73
endopeptidase activity 8 38 -2.04 1.88
calcium ion binding 24 71 -2.2 0.59
structural constituent of ribosome 5 51 -0.8 11.45
structural molecule activity 12 75 -1.62 7.63
hydrogen ion transmembrane transporter activity 5 18 0.73 4.68
ribonucleotide binding 65 95 -0.53 -3.21
signal transducer activity 64 91 -0.37 -3.24
transferase activity 83 97 1.63 -3.28
Cellular component
chromosome 28 11 3.91 -3.17
nucleolus 13 18 2.84 2.1
nucleus 207 329 2.43 -0.23
plasma membrane part 40 77 -2.25 -2.76
ribosome 6 59 -1.15 10.91
ribonucleoprotein complex 13 85 -1.69 8.59
macromolecular complex 80 228 -1.12 5.79
chromosomal part 22 9 3.39 -2.77
intrinsic to membrane 163 281 -0.89 -2.58
membrane 230 417 -1.46 -2.43
Specific ontologies, with some of the highest and lowest z-scores, were selected after the analysis of non-transformed data. A
z-score  is a statistical rating of the relative expression of gene ontologies, and shows how much each ontology is over- or under-
represented in a given gene list. In other words, the z-score is a standardized difference using the expected value and standard
deviation of the number of genes meeting the criterion of a gene ontology term under a hypergeometric distribution [97]. Positive
z scores represent gene ontology terms with a greater number of genes meeting the criterion than is expected by chance, whereas
negative z scores reflect gene ontology terms with fewer genes meeting the criterion than expected by chance. A z score close
to zero indicates that the number of genes meeting the criterion approximates the expected number [97]. Z-scores with values
>2.0 or less than <-2.0, and with ≥20 genes, are shown for selected ontologies. High and low values for the placebo and
testosterone groups in designated ontologies are highlighted in bold print. Terms: Testosterone genes ↑ - number of genes up-
regulated in lacrimal glands of testosterone-treated mice, as compared to those of the ‘placebo’ group; Placebo genes ↑ - number
of genes up-regulated in lacrimal glands of placebo-treated mice, relative to those of the ‘testosterone’ group; z-score - specific
score for the up-regulated genes in the placebo- and hormone-treated lacrimal glands.
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1558genes in female lacrimal and meibomian glands, respectively.
Comparative analyses showed that, with the exception of 4
genes, all lacrimal gland genes were increased or decreased
in the same direction in males. The 4 exceptions were genes
that were significantly reduced (ratios between 2.5 to 3.6 fold)
by testosterone in female mice, but were not lower following
androgen exposure in male lacrimal tissues (Table 11). In the
meibomian  gland  the  expression  of  2  genes,  that  were
significantly decreased (ratios=1.4 fold) in female tissues,
were significantly increased (ratios=1.3 fold) in males (Table
11). Another 13 genes in the female meibomian gland, that
showed significant expression differences (ratios between 1.4
to 1.8 fold) after testosterone exposure, were not influenced
in  the  same  direction  in  males  (Table  11).  Overall,  these
comparisons did not reveal any gene that was unique to female
lacrimal or meibomian glands.







      z-score  z-score
Biological Process
cellular catabolic process 66 12 5.53 -0.5
oxidation reduction 53 5 5.46 -1.72
protein transport 45 3 3.44 -2.49
cell communication 72 48 -4.85 0.47
signal transduction 58 41 -5.16 0.16
regulation of biological process 151 96 -6.67 1.34
immune response 16 24 -1.26 5.6
organ development 40 50 -4.34 4.43
response to stimulus 56 51 -3.32 3.68
protein transport 45 3 3.44 -2.49
protein localization 49 4 3.15 -2.53
macromolecule localization 51 4 3.25 -2.62
Molecular Function
oxidoreductase activity 57 8 5.81 -0.88
catalytic activity 258 58 5.36 -2.7
peptidase activity 33 10 2.4 0.51
DNA binding 39 35 -4.57 1.33
molecular transducer activity 31 32 -4.63 1.56
signal transducer activity 31 32 -4.63 1.56
receptor binding 18 19 -2.05 2.59
receptor activity 23 29 -4.5 2.05
nucleotide binding 80 19 0.06 -2.28
Cellular Component
mitochondrion 82 11 6.19 -1.2
cytoplasm 341 76 6.1 -2.67
organelle membrane 59 10 5.64 -0.18
cytoskeleton 21 15 -2.76 0.62
nucleus 149 65 -3.02 0.15
plasma membrane 53 51 -6.25 2.21
extracellular space 8 16 -2.57 3.83
plasma membrane part 20 33 -5.21 3.22
extracellular region part 29 19 -0.44 2.49
intracellular part 425 124 2.81 -2.17
cytoplasmic part 235 40 7.44 -2.47
cytoplasm 341 76 6.1 -2.67
Specific ontologies, with some of the highest and lowest z-scores, were selected following the analysis of non-transformed data.
Criteria  for inclusion in the Table were an ontology containing ≥20 genes and having a z-score >2.0 or <-2.0. High and low
values for the placebo and testosterone groups in designated ontologies are highlighted in bold print.
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1560Additional comparisons demonstrated that many of the
androgen effects on biological process, molecular function
and cellular component ontologies in lacrimal and meibomian
glands were the same in both females and males (data not
shown).
Comparative  effects  of  testosterone,  17β-estradiol  and/or
progesterone  on  gene  expression  in  female  lacrimal  and
meibomian glands: We have found that 17β-estradiol and/or
progesterone administration for 2 weeks significantly alters
the  expression  of  hundreds  of  genes  in  the  lacrimal  and
meibomian glands of ovariectomized mice [41,42] (Table 12).
To determine whether these sex steroid actions are unique, or
the same as, or opposite to, those elicited by testosterone
exposure,  we  compared  the  data  from  our  previous
investigations  (n=14  glands/  sample/  experiment;  n=3
experiments/ study) [41,42] to those in the current study. The
ages of the BALB/c mice used in all experiments were similar.
In addition, all gene expression results were obtained with
CodeLink  Uniset  Mouse  I  Bioarrays  and  analyzed  with
GeneSifter software.
As shown in Table 12 and Table 13, the majority of genes
regulated by testosterone, 17β-estradiol and/or progesterone
TABLE 7. ANDROGEN INFLUENCE ON GENES LINKED TO KERATINIZATION AND CELL FATE COMMITMENT IN THE FEMALE MEIBOMIAN GLAND.
Up-regulation Down-regulation
Keratinization Keratinization
  Small proline-rich protein 2A
  Small proline-rich protein 2B
  Small proline-rich protein 3
  Keratin 17
  Cornifelin
  Periplakin
  Transglutaminase 1, K polypeptide
Cell fate commitment Cell fate commitment
POU domain, class 2, transcription factor 1 Notch gene homolog 2
Cell division cycle 42 homolog (S. cerevisiae) Notch gene homolog 1
  Multiple endocrine neoplasia 1
  Delta-like 3
  GS homeobox 1
  Kinase insert domain protein receptor
  Sine oculis-related homeobox 1 homolog
  T-cell acute lymphocytic leukemia 1
Genes were significantly (p <0.05) up- or down-regulated by testosterone treatment.
TABLE 8. CONFIRMATION OF SELECTED CODELINK BIOARRAY RESULTS.
Accession number Gene CodeLink Ratios qPCR Ratios
Lacrimal gland
Testosterone>Placebo
NM_009735 β-2 Microglobulin 2.6; 3.4; 3.6 6.8; 9.4; 10.0
NM_011978 Solute carrier family 27, member 2 4.4; 3.7; 4.0 8.0; 10.0; 18.9
NM_009031 Retinoblastoma binding protein 7 4.0; 3.0; 3.2 4.4; 3.4; 4.8
Placebo>Testosterone
NM_018874 Pancreatic lipase related protein 1 77.3; 91.3; 73.0 2,121; 680; 320
NM_009714 Asialoglycoprotein receptor 1 10.0; 21.3; 14.8 7.1; 35.9; 52.1
NM_010726 Phytanoyl-CoA-hydroxylase 6.1; 7.1; 5.8 13.1; 13.2; 20.4
Meibomian gland
Testosterone>Placebo
NM_008161 Glutathione peroxidase 3 3.6; 3.0; 2.2 5.7; 3.8; 5.0
NM_026523 Neuromedin B 2.5; 2.3; 1.9 2.1; 1.8; 1.5
Placebo>Testosterone
NM_011468 Small proline-rich protein 2A 3.9; 3.6; 2.5 5.3; 7.3; 4.9
NM_022984 Resistin 2.0; 2.1; 2.9 3.6; 2.9; 2.5
The expression of designated genes, that were shown to be significantly altered in lacrimal and meibomian glands of placebo-
or testosterone-treated mice by using CodeLink Biooarrays, were re-examined with qPCR procedures. The relative ratios of
gene expression in 3 separate experiments are listed in the CodeLink and qPCR “Ratios” columns.
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1561in  the  lacrimal  and  meibomian  glands  were  unique  (i.e.
hormone-specific).  Treatment  with  17β-estradiol,
progesterone, or both sex steroids in combination significantly
influenced less than 6.4% of genes controlled by androgens
(Table 13). Conversely, testosterone significantly influenced
less than 23.3% of estrogen- and progestin-regulated genes
(Table 13).
However, although the total number of common genes
was  limited,  the  nature  of  the  hormone  response  to
testosterone, as compared to 17β-estradiol, progesterone or
both hormones together, was typically different. Between 62.3
to 68.8% of the sex steroid effects (i.e. testosterone versus
other hormones) in the lacrimal gland were in the opposite
direction. Moreover, between 45.2 to 54.0% of the hormone
responses  in  the  meibomian  gland  were  in  the  opposite
direction.  Examples  of  estrogen-  and  progestin-regulated
genes that were modulated in a similar or opposite manner
relative to testosterone are shown in Table 14 and Table 15.
DISCUSSION
Our  findings  demonstrate  that  testosterone  regulates  the
expression  of  thousands  of  genes  in  the  lacrimal  and
meibomian glands of ovariectomized mice. The magnitude
and extent of these hormonal effects, which encompassed
numerous biological, molecular and cellular ontologies, was
tissue-dependent.  Particularly  notable  was  the  androgen
stimulation  of  meibomian  gland  genes  related  to  lipid
metabolic pathways, and the suppression of genes associated
with  keratinization.  Many  of  the  genes  regulated  by
testosterone  in  female  tissues  were  identical  to  those
controlled  by  androgens  in  male  lacrimal  and  meibomian
glands.  However,  some  genes  were  modulated  in  a  sex-
specific  manner.  In  addition,  a  number  of  the  androgen-
regulated genes in female glands were altered in the opposite
direction by 17β-estradiol and/or progesterone. Overall, our
results support our hypothesis that sex steroids may induce
sex-specific  and  opposite  effects  in  the  lacrimal  and
meibomian glands.
Our  observation  that  testosterone  influences  the
expression of multiple genes in female ocular adnexal tissues
was anticipated. Androgens are known to exert a tremendous
impact on the structure and function of the lacrimal gland,
including such aspects as the cellular morphology, nuclear
architecture,  protein  synthesis,  enzyme  activity,  receptor
expression and fluid and protein secretion [28]. Similarly, the
meibomian gland is an androgen target organ, and androgens
appear to regulate this tissue’s function (e.g. lipid production)
[22-25,43-45]. Androgen deficiency, in turn, has been linked
to  lacrimal  and  meibomian  gland  dysfunction,  and  a
corresponding aqueous tear deficiency and evaporative dry
eye [22-26,28-30]. A number of these ocular effects, due to
the presence or absence of androgens, may be associated with
glandular alterations in gene activity [39,40].
Of the many androgen actions on gene expression in the
lacrimal and meibomian glands, two that stand out are the
stimulation of meibomian gland genes associated with lipid
metabolic pathways, and the suppression of genes related to
keratinization. First, the upregulation of genes involved with
lipid biosynthesis, transport, and metabolism is reminiscent
of testosterone’s similar influence on the male meibomian
gland  [39,46,47].  Androgens  stimulate  numerous  lipid
pathway  genes  in  this  tissue,  including  those  related  to
lipogenesis,  steroidogenesis,  and  cholesterogenesis  [39,46,
47]. Second, the testosterone downregulation of meibomian
gland genes associated with keratinization may explain on a
molecular  level  how  androgens  inhibit  this  process.
Keratinization is believed to be a primary cause of meibomian
gland  dysfunction  [48,49],  which  leads  to  tear  film
hyperosmolarity  and  instability  and  evaporative  dry  eye
[50-53].  Androgens  appear  to  prevent  this  keratinization,
because androgen insufficiency (e.g. during anti-androgen
treatment, complete androgen insensitivity syndrome and/or
aging) is associated with keratinization of the meibomian
gland ductal epithelium (i.e. orifice metaplasia) and the lid
[22,25,54]. It may be that these combined androgen actions,
promoting lipogenesis and suppressing keratinization, are the
reason  why  topical  androgens  reportedly  enhance  the
synthesis and secretion of meibomian gland lipids, prolong
the tear film breakup time, and alleviate dry eye syndrome
[44,45].
Testosterone's  effects  on  the  female  lacrimal  and
meibomian  gland  most  likely  involve  an  association  with
TABLE 9. SIMILAR AND OPPOSITE EFFECTS OF TESTOSTERONE ON GENE EXPRESSION IN FEMALE LACRIMAL AND MEIBOMIAN GLANDS.
Testosterone effect




Lacrimal Gland ↑, Meibomian Gland ↑ 58 54 59
Lacrimal Gland ↑, Meibomian Gland ↓ 26 30 31
Lacrimal Gland ↓, Meibomian Gland ↑ 153 141 154
Lacrimal Gland ↓, Meibomian Gland ↓ 64 67 68
Data were analyzed with and without log transformation (“Transform”). The expression of the same genes was significantly (p
<0.05) up (↑)- or down (↓)-regulated by androgen treatment of ovariectomized mice.
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1564saturable,  high-affinity  and  androgen-specific  receptors  in
acinar epithelial cell nuclei. Androgen receptors are members
of the steroid/thyroid hormone/retinoic acid family of ligand-
activated  transcription  factors  and  mediate  the  classical
actions  of  androgens  throughout  the  body  [55,56].  After
androgen binding to the receptor, the monomeric, activated
hormone-receptor  complex  associates  with  an  androgen
response element in the regulatory region of specific target
genes,  typically  dimerizes  with  another  androgen-bound
complex and, in combination with appropriate coactivators
and  promoter  elements,  modulates  gene  transcription  [55,
56].  In support of this hypothesis, androgen receptors have
been  shown  to  exist  in  lacrimal  and  meibomian  gland
epithelial cells [57-63] and androgen activity in these cells
may  be  compromised  by  androgen  receptor  mutations  or
antagonists [22-25,64-69]. Another mechanism of androgen
action may involve binding to glandular membrane receptors,
stimulation of signal transduction cascades and consequent
alteration of gene transcription [56,70]. Testosterone may also
act indirectly, by regulating the release of anterior pituitary
hormones that may influence the lacrimal and meibomian
glands.
Many of the genes modulated by testosterone in female
tissues are identical to those regulated by androgens in male
lacrimal and meibomian glands. However, some genes are
controlled  in  a  sex-specific  manner.  There  were  4  genes
downregulated by testosterone in the female, but not male,
lacrimal gland. These include lymphocyte antigen 78, which
is involved in innate immunity [70], a potassium voltage-
gated channel member, and homer protein homolog 3, that
helps couple surface receptors to intracellular calcium release
[71]. In the meibomian gland, several genes were upregulated
in the female, but not male, including prostaglandin (PG) E
synthase 2 (catalyzes the conversion of PG H2 to PG E2
[71]), estrogen related receptor α (may modulate the estrogen
signaling  pathway  [71]),  and  tropomodulin  4  (blocks  the
elongation and depolymerization of actin filaments [71]). In
addition,  a  series  of  meibomian  gland  genes  were
downregulated by testosterone solely in the female, such as
glial fibrillary acidic protein (an intermediate filament [71]),
chemokine  (C-C  motif)  ligand  7  (attracts  monocytes  and
eosinophils [71])  and  interleukin 1β.  Our analyses  did not
identify  any  gene  that  was  uniquely  and  significantly
expressed in female, as compared to male, glands.
TABLE 12. SIMILARITIES AND DIFFERENCES BETWEEN THE NUMBERS OF GENES REGULATED BY TESTOSTERONE, 17β-ESTRADIOL AND
PROGESTERONE IN THE LACRIMAL AND MEIBOMIAN GLANDS OF OVARIECTOMIZED MICE.
 Sex steroid effect
on gene expression
Lacrimal               Meibomian
gland                        gland
Testosterone ↑ 725 693
Testosterone ↓ 1304 273
17β-Estradiol ↑ 175 82
17β -Estradiol ↓ 188 87
Progesterone ↑ 93 25
Progesterone ↓ 137 134
17β -Estradiol + Progesterone ↑ 144 101
17β -Estradiol + Progesterone ↓ 198 188
17β -Estradiol ↑, Testosterone ↑ 13 12
17β -Estradiol ↓, Testosterone ↓ 17 5
17β -Estradiol ↑, Testosterone ↓ 24 1
17β -Estradiol ↓, Testosterone ↑ 42 13
Progesterone ↑, Testosterone ↑ 9 0
Progesterone ↓, Testosterone ↓ 13 11
Progesterone ↑, Testosterone ↓ 2 0
Progesterone ↓, Testosterone ↑ 19 12
17β -Estradiol + Progesterone ↑, Testosterone ↑ 17 12
17β -Estradiol + Progesterone ↓, Testosterone ↓ 29 11
17β -Estradiol + Progesterone ↑, Testosterone ↓ 30 4
17β -Estradiol + Progesterone ↓, Testosterone ↑ 46 23
The number of genes significantly (p <0.05) up (↑)- or down (↓)-regulated by steroid treatment of castrated mice is shown in
the columns entitled “Lacrimal gland” and “Meibomian gland.” Results were obtained by comparing log-transformed data. The
17β-estradiol and progesterone data originated from other studies [42,43], for which the Association for Research in Vision and
Ophthalmology is the copyright holder.
Molecular Vision 2009; 15:1553-1572 <http://www.molvis.org/molvis/v15/a166> © 2009 Molecular Vision
1565We were especially interested in comparing the effects of
the different sex steroids on gene expression in the lacrimal
and meibomian glands. Androgens, estrogens and progestins
play essential roles in the health and well-being of both men
and women [72,73]. However, these hormones may also have
antagonistic effects. An example is the influence of androgens
and estrogens on the sebaceous gland. Androgens regulate the
development,  differentiation  and  lipid  production  of
sebaceous glands throughout the body [74-78], and many of
these actions appear to involve androgen receptors and the
control  of  gene  transcription  in  acinar  epithelial  cells
[78-82]. Conversely, estrogens reduce the size, activity and
lipid output of sebaceous glands [74,76,82-86] and for years
were used clinically to decrease sebaceous gland function and
secretion [74,75,84,85,87,88]. One mechanism proposed for
estrogen action is that this hormone induces the release of
lysosomal enzymes within sebocytes, resulting in premature
cellular destruction and attenuated sebum elaboration [86,
89].  Additional  mechanisms,  though,  are  that  estrogens
decrease  testosterone  uptake,  interfere  with  testosterone's
conversion to dihydrotestosterone, and antagonize androgen
action in the sebaceous gland [15,83,86]. Indeed, estrogens
have been described as the mainstay of treatment to reduce
androgen effects on the sebaceous gland [75]. These 'anti-
androgen' actions of estrogens are dose-dependent, and may
be  overridden  by  exposure  to  physiological  levels  of
androgens [74,84].
Androgen treatment also causes a significant decrease in
the  number  of  estradiol  binding  sites  [89,90],  and  both
hormones antagonize each other's regulation of their own
receptor [15], in sebaceous glands. Indeed, some androgen
effects  are  thought  to  be  dependent  upon  low  levels  of
estrogen  [91].  This  steroid  antagonism  is  not  limited  to
androgens  and  estrogens.  Androgens  and  progestins,  for
instance,  may  also  show  opposite  effects  on  the  same
processes [92].
In  the  lacrimal  and  meibomian  glands,  a  number  of
identical genes were influenced by testosterone, and 17β-
estradiol and/or progesterone. The nature of the gene response
to these hormones was sometimes similar, but often opposite.
One lacrimal gland gene upregulated by 17β-estradiol and
downregulated by testosterone is asialoglycoprotein receptor
1, which has been linked to the development of exocrine gland
inflammation and dry eye [93-95]. These differential actions
could contribute to the estrogen pro-inflammatory [33], and
the androgen anti-inflammatory [33-36], effects in lacrimal
tissue  in  Sjögren's  syndrome.  Genes  stimulated  by
testosterone,  but  suppressed  by  17β-estradiol,  in  the
meibomian  gland  include  secreted  acidic  cysteine  rich
glycoprotein (regulates cell growth [71]), vascular endothelial
growth factor A (promotes cell migration, among many other
actions  [71]),  matrix  metalloproteinase  3  (degrades
fibronectin,  laminin,  gelatins  and  collagens  [71])  and
cathepsin  K  (degrades  extracellular  matrices  [71]).  These
TABLE 13. PERCENTAGES OF THE SAME GENES INFLUENCED BY TESTOSTERONE, 17β-ESTRADIOL AND/OR PROGESTERONE IN THE
LACRIMAL AND MEIBOMIAN GLANDS OF OVARIECTOMIZED MICE
Sex steroid effect on
gene expression
Lacrimal gland                                      Meibomian gland
E2±Prog/Test %     Test/E2±Prog %          E2±Prog/Test % Test/E2±Prog %
E2↑, Test↑ 1.8 7.4 1.7 14.6
E2↓, Test↓ 1.3 9.0 1.8 5.7
E2↑, Test↓ 1.8 13.7 0.004 1.2
E2↓, Test↑ 5.8 22.3 1.9 14.9
Prog↑, Test↑ 1.2 9.7 0 0
Prog↓, Test↓ 1.0 9.5 4.0 8.2
Prog↑, Test↓ 0.002 2.2 0 0
Prog↓, Test↑ 2.6 13.9 1.7 9.0
E2+ Prog↑, Test↑ 2.3 11.8 1.7 16.8
E2+ Prog↓, Test↓ 2.2 14.6 4.0 5.9
E2+ Prog↑, Test↓ 2.3 20.8 1.5 4.0
E2+ Prog↓, Test↑ 6.3 23.2 3.3 12.2
The percentages were calculated by dividing the number of genes significantly (p <0.05) up (↑)- or down (↓)-regulated by a
given  sex steroid treatment by the number of genes significantly (p <0.05) influenced by a different hormone(s), and multiplying
that fraction by 100. The gene numbers used for these calculations are reported in Table 12. Abbreviations: E2=17β-estradiol;
Prog=progesterone; Test=testosterone
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1568genes  could  theoretically  be  involved  in  cell  maturation,
migration and holocrine secretion in the meibomian gland. If
so, this would be consistent with a pro-sebaceous effect of
androgens and an anti-sebaceous activity of estrogens. Such
opposite effects of androgens and estrogens could also involve
post-transcriptional [14] and non-genomic [96] pathways.
In summary, our data demonstrate that testosterone, 17β-
estradiol  and  progesterone  exert  multiple  effects  on  the
lacrimal and meibomian glands, and that certain of these sex
steroid actions are sex-specific and/or opposite. It is quite
possible that these opposing sex steroid effects may play a role
in the pathogenesis of dry eye syndrome.
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